Analystreport

Turning Point Therapeutics, Inc. (NASDAQ: TPTX) had its price target lowered by analysts at Stifel Nicolaus from $50.00 to $45.00. They now have a "hold" rating on

Turning Point Therapeutics, Inc. - Common stock  (TPTX) 
Last turning point therapeutics, inc. - common stock earnings: 3/16 09:00 am Check Earnings Report